Journal
PLOS ONE
Volume 7, Issue 10, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0046437
Keywords
-
Categories
Funding
- Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS), France
- Sanofi Aventis
- Pfizer
- Bristol-Myers-Squibb
- Abbott
- Boehringer-Ingelheim
- Gilead Sciences
- Glaxo-Smith-Kline
- Janssen
- Merck-Sharp Dohme-Chibret
- Roche
- ViiV Healthcare
- ThermoFisher Scientific
- BRAHMS biomarkers
- BioMerieux
- Radiometer
- Philips
- ThermoFisher Brahms
- OctoPharma
- LFB
- Sangart
- Sigma Tau
- Novartis
- Sanofi
Ask authors/readers for more resources
Objective: In October 2009 the French National Authority for Health recommended that HIV testing be proposed at least once to all persons aged 15 to 70 years in all healthcare settings. We examined whether routine HIV screening with a rapid test in emergency departments (EDs) was feasible without dedicated staff, and whether newly diagnosed persons could be linked to care. Methods: This one-year study started in December 2009 in 6 EDs in the Paris area, using the INSTI (TM) test. Eligible individuals were persons 18 to 70 years old who did not present for a vital emergency, for blood or sexual HIV exposure, or for HIV screening. Written informed consent was required. Results: Among 183 957 eligible persons, 11 401 were offered HIV testing (6.2%), of whom 7936 accepted (69.6%) and 7215 (90.9%) were tested (overall screening rate 3.9%); 1857 non eligible persons were also tested. Fifty-five new diagnoses of HIV infection were confirmed by Western blot (0.61% (95% CI 0.46-0.79). There was one false-positive rapid test result. Among the newly diagnosed persons, 48 (87%) were linked to care, of whom 36 were not lost to follow-up at month 6 (75%); median CD4 cell count was 241/mm(3) (IQR: 52-423/mm(3)). Conclusions: Screening rates were similar to those reported in opt-in studies with no dedicated staff. The rate of new diagnoses was similar to that observed in free anonymous test centres in the Paris area, and well above the prevalence (0.1%) at which testing has been shown to be cost-effective.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available